The potential use of sPD-L1 as a tumor marker itself is also discussed, and its relation to other clinical and pathological variables that predict prognosis in CCRCC and treatment response in metastatic CCRCC, according to MASS criteria, is investigated. Here, SPDL1 is linked to nonpapillary renal cell carcinoma.